, Tracking Stock Market Picks
Enter Symbol:
Genvec, Inc. (GNVC) [hlAlert]

Market Outperform
up 376.92 %

Genvec, Inc. (GNVC) rated Market Outperform with price target $2 by Boenning & Scattergood

Posted on: Friday,  Nov 21, 2008  8:25 AM ET by Boenning & Scattergood

Boenning & Scattergood rated Market Outperform Genvec, Inc. (NASDAQ: GNVC) on 11/21/2008, when the stock price was $0.52.
Since then, Genvec, Inc. has gained 376.92% as of 08/27/2015's recent price of $2.48.
If you would have followed this Boenning & Scattergood's recommendation on GNVC, you would have gained 376.92% of your investment in 2470 days.

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade is currently in a pivotal Phase II/III study in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and metastatic melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease.

Our equity research team concentrates on companies that aren’t widely covered in sectors such as water distribution/equipment/technology, financial services, business services, aerospace & defense technology, medical technology and retail.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/21/2008 8:25 AM Buy
0.52 2.00
as of 12/24/2008
1 Week up  23.07 %
1 Month up  56.09 %
3 Months up  48.83 %
1 YTD up  48.83 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy